Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion ... weight loss and diabetes drug market. Eli Lilly is developing an obesity pill that would ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The best under-desk treadmills are a great way to keep moving while working. These walking ...

Separately, Eli Lilly said that it expects its new weight loss pill to be approved by U.S. regulators in 2026. The Indianapolis, Indiana-based company said that it will release late-stage trial ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

1.6 million people are set to be offered the ... Similar concerns arose for its oral weight-loss pill. Unsurprisingly, when it comes to developing weight loss drugs, something of an arms race ...